Suchergebnisse - "Yokoyama, Keitaro"

PubPharm (317)

21

Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis : The LANDMARK Randomized Clinical Trial

enthalten in: JAMA | 2021

von Ogata, H. | Fukagawa, M. | Hirakata, H. | +104

22

Comparisons of Clinical Outcomes in Patients Transferred to Combined Therapy with Peritoneal Dialysis and Hemodialysis over those Directly Transferred to Hemodialysis: A Prospective Multicenter Study in Japan

enthalten in: ResearchSquare.com | 2021

von Maruyama, Y. | Yokoyama, K. | Higuchi, C. | +8

23

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism : results of a post-marketing surveillance in Japan

enthalten in: Clinical and experimental nephrology | 2021

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +5

24

Comparison of peritoneal function within the first 1 year of peritoneal dialysis between diabetic and non‐diabetic patients

enthalten in: Therapeutic Apheresis and Dialysis | 2021

von Asari, K. | Maruyama, Y. | Kishida, K. | +7

25

A disposable, ultra-fine endoscope for non-invasive, close examination of the intraluminal surface of the peritoneal dialysis catheter and peritoneal cavity

enthalten in: Scientific reports | 2020

von Nakayama, M. | Hamada, C. | Yokoyama, K. | +12

26

Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism

enthalten in: Nephrology (Carlton, Vic.) | 2020

von Shigematsu, T. | Fukagawa, M. | Yokoyama, K. | +4

27

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

enthalten in: Clinical and experimental nephrology | 2020

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +5

28

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

enthalten in: Clinical and experimental nephrology | 2020

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +5

29

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

enthalten in: Clinical and experimental nephrology | 2020

von Yokoyama, K. | Fukagawa, M. | Shigematsu, T. | +5

30

Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients

enthalten in: Human cell | 2020

von Nakashima, A. | Ichida, K. | Ohkido, I. | +9